Sukumar Nagendran - 21 Aug 2025 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: President and Head of R&D, Director
Signature: /s/ Kamran Alam
Issuer symbol: TSHA
Transactions as of: 21 Aug 2025
Net transactions value: -$162,604
Form type: 4
Filing time: 22 Aug 2025, 16:15:17 UTC
Previous filing: 13 Jun 2025
Next filing: 12 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nagendran Sukumar	President and Head of R&D, Director	C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS	/s/ Kamran Alam	22 Aug 2025	0001665124

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Sale	$162,604	-57,054	-4.7%	$2.85	1,165,289	21 Aug 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.